Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxatag vs Penicillin VK in Strep Throat
NCT00095368Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2004
- Countries
- 1
- Sponsor
- Advancis Pharmaceuticals
- Modality
- Small Molecules
- Drugs
- amoxicillin
- Conditions
- streptococcal pharyngitis
01
Overview
Phase 3, randomised, double-blind trial of amoxicillin in streptococcal pharyngitis (2 arms), sponsored by Advancis Pharmaceuticals. Primary endpoint: Bacteriological outcome at the Test of Cure Visit. Started Oct 2004; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Moxatag Arm
APC-111 775 mg MP Tablet QD for 7 days
Penicillin VK Arm
Penicillin VK 250 mg QID for 10 days
03
Who it enrols
Patients aged 12 and over with a clinical diagnosis of acute pharyngitis or tonsillitis and a positive rapid Strep test.
04
Endpoints
Primary
Bacteriological outcome at the Test of Cure Visit
Secondary
Bacteriological outcome at the Late Post Therapy Visit
Clinical Outcome
Safety
Beyond the preview
Go deeper on NCT00095368.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095368.